Duration of adjuvant immune checkpoint inhibitors in hepatocellular carcinoma with high-risk recurrence factors: A prospective, multicentric cohort study

被引：0
|
作者：
Su, J-Y. [1 ]
Liu, S. [2 ]
Xu, X-L. [3 ]
Ou, J-J. [4 ]
Li, L. [1 ]
Ma, Y-L. [5 ]
Ma, L. [1 ]
Zhong, J-H. [1 ]
机构：
[1] Guangxi Med Univ, Canc Hosp, Hepatobiliary Surg, Nanning, Peoples R China
[2] Guangxi Med Univ, Affiliated Hosp 8, Hepatobiliary Surg, Guigang, Peoples R China
[3] Peoples Hosp Wuzhou, Med Records & Stat Room, Wuzhou, Peoples R China
[4] Wuzhou Peoples Hosp, Hepatobiliary Surg, Wuzhou, Peoples R China
[5] Guangxi Med Univ, Canc Hosp, Pathol, Nanning, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.233
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
213P
引用
收藏
页码：S1485 / S1486
页数：2
相关论文
共 50 条
  • [31] RISK FACTORS FOR CHOLANGIOCARCINOMA IN KOREAN ADULTS AND COMPARISON WITH HEPATOCELLULAR CARCINOMA: A PROSPECTIVE COHORT STUDY
    Cho, In Rae
    Yi, Jee-Jeon
    Yi, Sang-Wook
    GASTROENTEROLOGY, 2020, 158 (06) : S1295 - S1296
  • [32] Comparison of Risk Factors for Cholangiocarcinoma and Hepatocellular Carcinoma: A Prospective Cohort Study in Korean Adults
    Cho, In Rae
    Yi, Sang-Wook
    Choi, Ja Sung
    Yi, Jee-Jeon
    CANCERS, 2022, 14 (07)
  • [33] Immune checkpoint inhibitor rechallenge in advanced hepatocellular carcinoma: A retrospective cohort study
    Chen, J-K.
    Su, J-Y.
    Peng, N-F.
    Ma, L.
    Zhong, J-H.
    ANNALS OF ONCOLOGY, 2024, 35 : S1490 - S1490
  • [34] Neurological adverse events of immune checkpoint inhibitors - a monocentric prospective cohort study
    Moehn, N.
    Narten, E.
    Duzzi, L.
    Mahjoub, S.
    Graalmann, T.
    Heoglinger, G.
    Kalinke, U.
    Beutel, G.
    Wirth, T.
    Vogel, A.
    Berliner, D.
    Bollmann, B.
    Gutzmer, R.
    Ivanyi, P.
    Grimmelmann, I.
    Skripuletz, T.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2022, 20 : 10 - 10
  • [35] Adjuvant donafenib for hepatocellular carcinoma patients at high-risk of recurrence after radical resection: a real-world experience
    Zhang, Shenyu
    Yang, Guibin
    Song, Ruipeng
    Wang, Wei
    Meng, Fanzheng
    Yin, Dalong
    Wang, Jiabei
    Zhang, Shugeng
    Cai, Wei
    Liu, Yao
    Luo, Dayong
    Wang, Jizhou
    Liu, Lianxin
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [36] Use of Adjuvant Sorafenib in Liver Transplant Recipients with High-Risk Hepatocellular Carcinoma
    Shetty, Kirti
    Dash, Chiranjeev
    Laurin, Jacqueline
    JOURNAL OF TRANSPLANTATION, 2014, 2014
  • [37] Unleashing the efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma: factors, strategies, and ongoing trials
    Yu, Jiahui
    Li, Mengnan
    Ren, Boxu
    Cheng, Le
    Wang, Xiaoxiao
    Ma, Zhaowu
    Yong, Wei Peng
    Chen, Xiaoguang
    Wang, Lingzhi
    Goh, Boon Cher
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [38] Features of myositis and myasthenia gravis in patients treated with immune checkpoint inhibitors: a multicentric, retrospective cohort study
    Plomp, Lotta
    Chassepot, Hortense
    Psimaras, Dimitri
    Maisonobe, Thierry
    Mensi, Eric
    Leonard-Louis, Sarah
    Plu, Isabelle
    Rozes, Antoine
    Tubach, Florence
    Touat, Mehdi
    Anquetil, Celine
    Wesner, Nadege
    Champtiaux, Nicolas
    Rigolet, Aude
    Demeret, Sophie
    Weiss, Nicolas
    Alyanakian, Marie-Alexandra
    Le Panse, Rozen
    Truffault, Frederique
    Dragon-Durey, Marie-Agnes
    Chatenoud, Lucienne
    Abbar, Baptiste
    Bretagne, Marie-Claire
    Procureur, Adrien
    Similowski, Thomas
    Morelot-Panzini, Capucine
    Dres, Martin
    Ederhy, Stephane
    Benveniste, Olivier
    Salem, Joe-Elie
    Allenbach, Yves
    LANCET REGIONAL HEALTH-EUROPE, 2025, 50
  • [39] Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors
    Chennamadhavuni, Adithya
    Abushahin, Laith
    Jin, Ning
    Presley, Carolyn J.
    Manne, Ashish
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [40] A prospective cohort study on the improvement of disease-free progression survival in patients with hepatocellular carcinoma by combining Sophora japonica granules with targeted and immune checkpoint inhibitors
    Li, Hui
    Zhang, Hongliang
    Zhang, Tong
    He, Wenting
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345